MED Medifast (MED) Insider Trading, Ownership & Congress Trades
Food & Beverage · Miscellaneous food preparations & kindred products · CIK 0000910329
Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
67
13F, latest reported quarter
What the filings say about MED
Insiders, 180 days
+$1.3M net bought
2 buyers · 1 seller · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$226.3K
2 notices
Medifast insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MEDIFAST INC insiders bought a net $1.3M of stock across 73 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (4 buys, 1 sale), the last on Sep 28, 2026.
- +2.7% median (+2.6% mean) 90-day return after 4 previous buys.
- The trade is 7.3% of the 130,609 shares held after it.
- No other insider sold within 30 days.
- 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Chard Daniel R sold about $112.0K of MED under a 10b5-1 plan on Sep 29, 2026; 67 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Mar 20, 2026.
- +2.7% median (+2.6% mean) 90-day return after 4 previous buys.
- The trade is 6.8% of the 140,153 shares held after it.
- No other insider sold within 30 days.
- 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Chard Daniel R sold about $114.3K of MED under a 10b5-1 plan on Sep 28, 2026, the largest insider sale at the company since 2023; 67 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Aug 24, 2026.
- The trade is 5.9% of the 707,492 shares held after it.
- No other insider bought within 30 days.
- 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kiai Parsa bought about $514.7K of MED on Aug 26, 2026, the largest insider purchase at the company on our record; 67 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Aug 24, 2026.
- The trade is 5.8% of the 20,270 shares held after it.
- No other insider bought within 30 days.
- 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kiai Parsa bought about $14.4K of MED on Aug 26, 2026; 67 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Aug 20, 2026.
- The trade is 0.6% of the 665,517 shares held after it.
- No other insider bought within 30 days.
- 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kiai Parsa bought about $50.5K of MED on Aug 24, 2026; 67 funds added in the latest 13F quarter.73 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.3M over 180 days
+$1.2M over 90 days
more than 91% of Food & Beverage
Congress
no House purchase disclosed in the last 12 months
Funds
67 funds bought in last quarter
below 69% of Food & Beverage
Revenue
-36.0% year over year
below 94% of Food & Beverage
Margin
-4.8% net margin
below 67% of Food & Beverage
Buybacks
no share repurchases reported
Short interest
12.4% of the float short (float per yahoo 2026-10-26) · 7.3 days to cover · settled 2026-09-30
more than 86% of Food & Beverage
What changed in the last 30 days
Sep 30Director Chard Daniel R sold $226.3K under a 10b5-1 plan (2 trades, Sep 28 to Sep 29)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 29Officer Chard Daniel R filed to sell $112.0K by Sep 29 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch MED
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-3.0%12M
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MED: institutional holders (13F)
13F holdings, latest reported quarter
778,610 sh
$8.3M
706,699 sh
$7.5M
481,381 sh
$5.1M
446,614 sh
$4.7M
396,996 sh
$4.2M
Congress trades in MED
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Steamboat Capital Partners, LLC
Activist 13D · 2026-03-20
6.0%
Parsa Kiai
Activist 13D · 2026-03-20
6.0%
MED planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Chard Daniel R
Filed 2026-09-29
$112.0K
Chard Daniel R
Filed 2026-09-28
$114.3K
MED mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$433.9K position · as of 2026-06-30
0.4%
Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value Fund
$416.9K position · as of 2026-06-30
0.2%
VANGUARD U.S. MULTIFACTOR FUND
$364.7K position · as of 2026-05-31
0.1%
Federated Hermes MDT Small Cap Core ETF
$357.1K position · as of 2026-05-31
0.1%
Ultra-Small Company Market Fund
$106.1K position · as of 2026-06-30
0.1%
Schwab Fundamental U.S. Small Company ETF
$4.7M position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Daniel Chard
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.6M
$2.7M
$1.3M
-94%
+16%
2024
$5.6M
$983.5K
$1.2M
-90%
+40%
2023
$7.0M
$2.9M
$1.7M
-61%
+39%
2022
$5.9M
-$710.7K
$1.2M
-37%
+20%
2021
$6.6M
$12.9M
$1.4M
+9%
+29%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.3M bought by insiders over 180 days, 67 funds added last quarter, $226.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MED financials
Revenue growth
-36.0%
XBRL, annual
Net margin
-4.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$316.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MED
| FY Dec 2025 | $385.8M |
| FY Dec 2024 | $602.5M |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $1.6B |
| FY Dec 2021 | $1.5B |
| Jun 2026 | $76.4M |
| Mar 2026 | $76.0M |
| Dec 2025 | $75.1M |
| Sep 2025 | $89.4M |
| Jun 2025 | $105.6M |
| Mar 2025 | $115.7M |
| Dec 2024 | $119.0M |
| Sep 2024 | $140.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-8.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MED
| FY Dec 2025 | -4.9% |
| FY Dec 2024 | +0.3% |
| FY Dec 2023 | +9.2% |
| FY Dec 2022 | +9.0% |
| FY Dec 2021 | +10.7% |
| Jun 2026 | -4.1% |
| Mar 2026 | -2.8% |
| Dec 2025 | -24.6% |
| Sep 2025 | -2.5% |
| Jun 2025 | +2.3% |
| Mar 2025 | -0.7% |
| Dec 2024 | +0.6% |
| Sep 2024 | +0.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MED
| FY Dec 2025 | $1.2M |
| FY Dec 2024 | $17.0M |
| FY Dec 2023 | $141.2M |
| FY Dec 2022 | $177.9M |
| FY Dec 2021 | $60.3M |
| Jun 2026 | $728.0K |
| Mar 2026 | -$836.0K |
| Dec 2025 | -$6.6M |
| Sep 2025 | $10.8M |
| Jun 2025 | -$4.8M |
| Mar 2025 | $1.9M |
| Dec 2024 | -$7.2M |
| Sep 2024 | $7.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity MED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt MED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-12.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MED
| FY Dec 2025 | -9.3% |
| FY Dec 2024 | +1.0% |
| FY Dec 2023 | +55.5% |
| FY Dec 2022 | +80.6% |
| FY Dec 2021 | +91.2% |
| Jun 2026 | -12.6% |
| Mar 2026 | -10.0% |
| Dec 2025 | -9.3% |
| Sep 2025 | +0.1% |
| Jun 2025 | +1.7% |
| Mar 2025 | -3.4% |
| Dec 2024 | +1.0% |
| Sep 2024 | +3.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-9.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MED
| FY Dec 2025 | -7.1% |
| FY Dec 2024 | +0.7% |
| FY Dec 2023 | +31.6% |
| FY Dec 2022 | +40.3% |
| FY Dec 2021 | +48.6% |
| Jun 2026 | -9.8% |
| Mar 2026 | -7.6% |
| Dec 2025 | -7.1% |
| Sep 2025 | +0.1% |
| Jun 2025 | +1.3% |
| Mar 2025 | -2.4% |
| Dec 2024 | +0.7% |
| Sep 2024 | +2.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital MED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-8.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MED
| FY Dec 2025 | -6.7% |
| FY Dec 2024 | +1.3% |
| FY Dec 2023 | +64.3% |
| FY Dec 2022 | +91.5% |
| FY Dec 2021 | +110.0% |
| Jun 2026 | -8.8% |
| Mar 2026 | -7.6% |
| Dec 2025 | -6.7% |
| Sep 2025 | -2.6% |
| Jun 2025 | +0.2% |
| Mar 2025 | -2.8% |
| Dec 2024 | +1.3% |
| Sep 2024 | +5.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MED
| FY Dec 2025 | n/a |
| FY Dec 2024 | 97.89x |
| FY Dec 2023 | 7.38x |
| FY Dec 2022 | 9.08x |
| FY Dec 2021 | 15.08x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 1,367.00x |
| Jun 2025 | 43.91x |
| Mar 2025 | n/a |
| Dec 2024 | 97.89x |
| Sep 2024 | 29.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value MED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield MED
| FY Dec 2025 | +1.1% |
| FY Dec 2024 | +8.8% |
| FY Dec 2023 | +19.3% |
| FY Dec 2022 | +14.1% |
| FY Dec 2021 | +2.5% |
| Jun 2026 | +3.4% |
| Mar 2026 | -1.3% |
| Dec 2025 | +1.1% |
| Sep 2025 | +0.4% |
| Jun 2025 | -1.6% |
| Mar 2025 | +9.1% |
| Dec 2024 | +8.8% |
| Sep 2024 | +16.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MED
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.25x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $385.8M | $602.5M | $1.1B | $1.6B |
| Gross profit | $275.2M | $444.6M | $775.9M | $1.1B |
| Operating income | -$14.2M | $2.9M | $126.4M | $184.8M |
| Net income | -$19.0M | $2.0M | $99.0M | $144.0M |
| EPS (diluted) | -1.70 | 0.19 | 9.10 | 12.73 |
| Operating cash flow | $6.9M | $24.5M | $147.7M | $194.6M |
| Cash | $89.3M | $90.9M | $94.4M | $87.7M |
| Buybacks | $0 | $0 | $3.6M | $126.4M |
| Dividends paid | $195.0K | $715.0K | $73.0M | $71.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
MED Stock Sonar score 5/7 axes
Find similar shapesCompareMED ranks highest on insider conviction (84th percentile) and risk and compliance (65th), and lowest on growth (6th), among Food & Beverage peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MED filings, in plain words
Are Medifast insiders buying or selling MED?
In the 180 days to 2026-10-28, Medifast insiders were net buyers, a net $1.3M: $1.5M of purchases and $226.3K of sales reported on Form 4, by 2 buyers and 1 seller.
Are there planned insider sales of MED?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $226.3K of stock; the latest, by Chard Daniel R, was filed 2026-09-29.
Read the full summary
In the 180 days to 2026-10-28, Medifast insiders were net buyers of MED, a net $1.3M across purchases and sales reported on Form 4 by 2 buyers and 1 seller. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $226.3K of stock. The latest 5% ownership filing is a 13D by Steamboat Capital Partners, LLC, filed 2026-03-20, for 6.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
